礼来公司：Orforglipron在Achieve-3研究中表现优于口服司美格鲁肽

Group 1 - The core finding of the article is that Eli Lilly's Orforglipron outperformed oral semaglutide in the Achieve-3 study, achieving all primary and key secondary endpoints [1] Group 2 - Orforglipron demonstrated significant efficacy in the study, indicating its potential as a competitive treatment option in the diabetes market [1] - The results may influence future treatment guidelines and market dynamics for diabetes medications [1] - Eli Lilly's advancements in this area could enhance its market position and drive growth in its pharmaceutical portfolio [1]